Thrombotic microangiopathy
MONDO:0019737The syndromes of microangiopathic hemolytic anemia, thrombocytopenia, and variable signs of organ impairment, due to platelet aggregation in the microcirculation.
154 clinical trials for this condition and its sub-types, 26 tagged with Thrombotic microangiopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Thrombotic microangiopathy
-
Thrombocytopenic purpura 8 trials · 116 incl. sub-types
2 sub-types
- Autoimmune thrombocytopenic purpura 95 trials
- Thrombotic thrombocytopenic purpura 15 trials · 20 incl. sub-types Sub-types →
-
Atypical hemolytic-uremic syndrome 19 trials
4 sub-types
Most studied deeper sub-types
-
Tailored drug regimen shows promise for rare blood disorder
Disease control Stopped earlyThis study tested whether giving the drug caplacizumab based on regular blood tests (ADAMTS13 activity) could improve outcomes for adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare condition causing dangerous blood clots. The trial enrolled 58 adults and mon…
Phase 2 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Promising aHUS drug trial stalls after only 6 patients enrolled
Disease control Stopped earlyThis study tested a drug called narsoplimab (OMS721) for atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and organ damage. The trial aimed to see if the drug could improve platelet counts and was safe for adults and adolescents. However, the st…
Phase 3 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Experimental drug iptacopan tested for rare blood disorders
Disease control Stopped earlyThis study tested an experimental drug called iptacopan in people with two rare blood disorders: immune thrombocytopenia (ITP) and cold agglutinin disease (CAD). The goal was to see if the drug could improve platelet counts in ITP or hemoglobin levels in CAD. The trial was termin…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC